Researchers have been excited about the medication , a novel dual agonist showing promising results in early trials for size loss . It acts by targeting both pathways : GLP-1 and GIP, these, when engaged , help influence hunger and boost calorie burn. Initial findings indicate substantial body loss and possible advantages for individuals dealing wi